Jeffrey Golden

MD

Associate Medical Director, Lung Transplant Program

About me

Dr. Jeffrey Golden, associate medical director of the UCSF Lung Transplant Program, is a pulmonologist who cares for patients with severe lung disease, particularly those who are candidates for lung transplants.

Golden is director of clinical trials (studies to evaluate new therapies) for the Interstitial Lung Disease Program. In 2010, one of his longtime patients, Nina Ireland, left $48 million – almost her entire estate – to UCSF, creating the Nina Ireland Program for Lung Health. The ambitious program supports creative, collaborative approaches to advancing patient care, professional training and research in pulmonary medicine.

Golden earned his medical degree at Washington University in St. Louis. He completed his training in both internal medicine and pulmonary medicine at UCSF. He completed pulmonary research training at the UCSF Cardiovascular Research Institute, where he studied ozone inhalation in humans as a model of asthma.

  • Education

    Washington University School of Medicine, 1972

  • Residencies

    UCSF Medical Center, Internal Medicine, 1975

  • Fellowships

    UCSF Medical Center, Pulmonary Medicine, 1977

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine/Pulmonary Disease

    Pulmonary Disease, American Board of Internal Medicine

  • Academic Title

    Professor

Conditions I specialize in

Interstitial Lung Disease (ILD) Program

400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143

(415) 353-2577

Lung Transplant Program

400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143

(415) 353-4145
Th, 8 a.m. - 5 p.m.

Pulmonary Practice at Parnassus

400 Parnassus Ave., Fifth Floor
San Francisco, CA 94143

(415) 353-2961
M-F, 8 a.m. - 5 p.m.
dr-jeff-golden-md-103-1440x818-2x

"I hope we can find medications so people like me, who do lung transplants, go out of business."

Selected research

Decorative Caduceus

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

Change from baseline, measured at 3-month intervals, in the mean forced vital capacity (represented as the percentage of the age-; height-; gender-; and race-adjusted predicted value, i.e. FVC-%).

Recruiting

Decorative Caduceus

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in...

Recruiting

My work

Our programs: ILD - Interstitial Lung Disease

Our stories: A second chance

Contact me

Providers on my team

Share